Dalbavancin vs standard antibiotics for catheter bloodstream infection
Part of Infections clinical trials.
This trial tests whether dalbavancin (an antibiotic given as a dose or doses) works as well as standard antibiotics to treat bloodstream infections related to a removed IV catheter caused by Staphylococcus aureus. It may help reduce treatment time and dosing complexity if you qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your blood cultures show Staphylococcus aureus, and the sample was taken within 72 hours before randomization
- You have a catheter-related bloodstream infection (likely tied to your catheter), and any involved catheter was removed before the study starts
- The infection is caused by one type of Staphylococcus aureus (not multiple germs), and the bacteria are not dalbavancin-resistant
- You have received no more than 72 hours of effective antibiotic treatment aimed at Staphylococcus aureus before randomization
- You can sign the informed consent form yourself
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the bacteria that can build up on IV lines to see if they increase the risk of infection. By examining these bacteria, researchers hope to find ways to reduce infections in patients who need IV treatment.
This study tests a better way to give a long-acting antibiotic called dalbavancin for serious bacterial infections. Dalbavancin is given as an infusion and may allow you to leave the hospital sooner while still completing your antibiotic treatment.
This study tests a new antibiotic called dalbavancin for treating infections of the heart valves. It may offer a simpler treatment option with fewer hospital visits.
This study looks back at patients who received the antibiotic dalbavancin as a long-term suppressive therapy for stubborn infections. It aims to see how well it worked and if it was safe.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
This trial tests whether an antibiotic called dalbavancin, given to prevent bacterial infections during chemotherapy-induced low white blood cell counts, is safe and works in children and young adults with certain types of leukemia. It may help reduce the risk of serious infections during treatment.
Hear when a new Staphylococcus Aureus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.